{"id":3111,"date":"2026-06-29T14:29:57","date_gmt":"2026-06-29T07:29:57","guid":{"rendered":"https:\/\/naviva.com.vn\/?p=3111"},"modified":"2026-07-29T09:41:08","modified_gmt":"2026-07-29T02:41:08","slug":"stability-of-the-second-generation-mav-06-varicella-vaccine-barycela-translating-scientific-evidence-into-immunization-practice","status":"publish","type":"post","link":"https:\/\/naviva.com.vn\/en\/stability-of-the-second-generation-mav-06-varicella-vaccine-barycela-translating-scientific-evidence-into-immunization-practice","title":{"rendered":"Stability of the Second-Generation MAV\/06 Varicella Vaccine \u2013 BARYCELA: Translating Scientific Evidence into Immunization Practice"},"content":{"rendered":"

For live attenuated vaccines, stability is a critical quality attribute that helps ensure product integrity throughout storage, transportation, and administration. Because live viruses may gradually lose potency over time or when exposed to suboptimal storage conditions, maintaining vaccine stability is essential to preserving product quality.<\/span><\/p>\n

The second-generation <\/span>MAV\/06 varicella vaccine \u2013 BARYCELA<\/b> has been developed with advanced manufacturing technologies and is supported by robust stability data.<\/span><\/span><\/p>\n

\"\"<\/a><\/p>\n

Image: BARYCELA Varicella Vaccine<\/span><\/i><\/p>\n

Maintains a Minimum Potency of 3,800 PFU Throughout Its Shelf Life<\/b><\/span><\/h2>\n

BARYCELA maintains a minimum potency of <\/span>3,800 Plaque Forming Units (PFU)<\/b> throughout its <\/span>24-month shelf life<\/b>. This minimum potency is higher than that specified for certain Oka-strain varicella vaccines currently used worldwide (1).<\/span><\/span><\/p>\n

 <\/p>\n\n\n\n\n\n
\u00a0<\/b><\/span><\/td>\nSecond-generation MAV\/06<\/b><\/span><\/td>\nOka\/Merck<\/b><\/span><\/td>\nOka\/RIT<\/b><\/span><\/td>\n<\/tr>\n
Shell Life<\/b><\/span><\/td>\n24 months<\/span><\/td>\n24 months<\/span><\/td>\n24 months<\/span><\/td>\n<\/tr>\n
Minimum PFU<\/b><\/span><\/td>\n3800<\/span><\/td>\n1350<\/span><\/td>\n1995<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

Table. Comparison of minimum PFU values among varicella vaccines<\/b><\/span><\/p>\n

In a multicenter Phase III clinical study, BARYCELA demonstrated <\/span>non-inferior immunogenicity and a comparable safety profile<\/b> to the Oka\/Merck varicella vaccine following vaccination (2).<\/span><\/span><\/p>\n

Stability Data Under Storage at 15\u00b0C for 28 Days<\/b><\/span><\/h2>\n

According to manufacturer stability studies, BARYCELA was stored under the following conditions:<\/span><\/p>\n